Modern Pediatrics. Ukraine. (2026).4(156): 43-49. doi: 10.15574/SP.2026.4(156).4349
Umanets T. R., Buratynska A. A., Kutsenok L. A., Malahova V. V., Lapshyn V. F.
SI «Ukrainian Center of Maternity and Childhood of the NAMN of Ukraine», Kyiv

For citation: Umanets TR, Buratynska AA, Kutsenok LA, Malahova VV, Lapshyn VF. (2026). Experience of using a combination of salbutamol sulphate, bromhexine hydrochloride, guaifenesin, menthol in children with acute bronchitis. Modern Pediatrics. Ukraine. 4(156): 43-49. doi: 10.15574/SP.2026.4(156).4349.
Article received: Mar 17, 2026. Accepted for publication: May 12, 2026.

Aim – to evaluate the clinical efficacy and tolerability of the combined preparation Ascoril Expectorant in children with acute bronchitis. 
Materials and methods. An open-label, prospective, observational ‘before-and-after’ study was conducted involving 50 children aged 4 to 12 years with acute bronchitis between January and March 2026. The frequency, intensity of coughing and volume of sputum were assessed using scoring scales by the doctor and the patients’ parents at screening and during the course of treatment (on days 3-4 and 8–10). Spirometry results were analysed for children over 6 years of age. Tolerability assessment included recording of all adverse effects, general clinical analyses, and 12-lead electrocardiography data.
Results. A statistically significant reduction in the frequency and intensity of coughing and a change in the nature of the cough to a productive one were observed on days 3-4 of treatment, with complete normalisation of auscultatory findings on days 8-10 of treatment, improvement in lung function parameters, and good tolerability of Ascoril Expectorant. Among adverse events, one episode of headache and mild tremor of the fingers was recorded in children of pubertal age.
Conclusions. The use of Ascoril Expectorant in children with acute bronchitis accompanied by frequent, unproductive cough is pathogenetically justified, leads to rapid regression of the disease and is well tolerated.
The study was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from the patients.
The authors declare that there is no conflict of interest.
Keywords: acute bronchitis, children, Ascoril Expectorant.

REFERENCES

1. Albrecht HH, Dicpinigaitis PV, Guenin EP. (2017). Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections. Multidiscip Respir Med. 12: 31. https://doi.org/10.1186/s40248-017-0113-4; PMid:29238574 PMCid:PMC5724298

2. Antipkin YuG, Lapshin VF, Umanets TR, Zadorozhnaya TD, Bondarenko YuM. (2025). Clinical and morphological characteristics of bronchitis in children. Kyiv: Creative Media: 256.

3. Balsamo R, Lanata L, Egan CG. (2010). Mucoactive drugs. Eur Respir Rev. 19(116): 127-133. https://doi.org/10.1183/09059180.00003510; PMid:20956181

4. Chin T. (2024). Acute Bronchitis in Childhood. In Bronchitis in Children – Latest Developments. IntechOpen. https://doi.org/10.5772/intechopen.111493

5. Jayaram S, Desai A. (2000) Efficacy and safety of Ascoril expectorant and other cough formula in the treatment of cough management in paediatric and adult patients – a randomised double-blind comparative trial. J Indian Med Assoc. 98(2): 68-70.

6. Lapshyn VF, Umanets TR. (2014). Mucolytic therapy in children with recurrent bronchitis. Perinatologiya i Pediatriya. 3(59): 36-40. doi: 10.15574/PP.2014.59.36.

7. Li Y, Wang X, Blau DM et al. (2022). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 399(10340): 2047-2064. https://doi.org/10.1016/S0140-6736(22)00478-0; PMid:35598608

8. Marushko YuV, Gishchak TV. (2020). Experience in using a combined expectorant drug for community-acquired pneumonia in preschool children. Family Medicine. 4(89): 82-86. https://doi.org/10.30841/2307-5112.4.2020.217968

9. Matyuha LF, Tytova TA, Tysh OB. (2020). Approaches to the Treatment of Cough in Acute Bronchitis in an Outpatient Setting. Family Medicine. (3): 67-74. https://doi.org/10.30841/2307-5112.3.2020.211948

10. Nurgozhin TS, Guliaev AE, Ermekbaeva BA, Zhaugasheva SK, Abuova GT, An ÉA. (2013). Results of international multicentre non-interventional clinical study of the effectiveness and safety of ascoril expectorant for the treatment of cough in Kazakhstan and Uzbekistan. Klinicheskaia meditsina. 91(6): 50-55.

11. Prabhu Shankar S, Chandrashekharan S, Bolmall CS, Baliga V. (2010). Efficacy, safety and tolerability of salbutamol + guaiphenesin + bromhexine (Ascoril) expectorant versus expectorants containing salbutamol and either guaiphenesin or bromhexine in productive cough: a randomised controlled comparative study. J Indian Med Assoc. 108(5): 313-314, 316-318, 320.

12. Sarfo JO, Amoadu M, Gyan TB et al. (2023). Acute lower respiratory infections among children under five in Sub-Saharan Africa: a scoping review of prevalence and risk factors. BMC Pediatr. 23(1): 225. https://doi.org/10.1186/s12887-023-04033-x; PMid:37149597 PMCid:PMC10163812

13. Schot MJC, Dekker ARJ, van Werkhoven CH et al. (2019). Burden of disease in children with respiratory tract infections in primary care: diary-based cohort study. Fam Pract. 36(6): 723-729. https://doi.org/10.1093/fampra/cmz024; PMid:31166598 PMCid:PMC7006994

14. Singh A, Avula A, Zahn E. (2024). Acute Bronchitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing. URL: https://www.ncbi.nlm.nih.gov/books/NBK448067/.

15. Sirota S, Bender R, Dominguez R et al. (2025). Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Infectious Diseases. 26: 343-361. doi: 10.1016/S1473-3099(25)00689.

16. Trusinska D, Zin ST, Sandoval E, Homaira N, Shi T. (2024). Risk Factors for Poor Outcomes in Children Hospitalized with Virus-associated Acute Lower Respiratory Infections: A Systematic Review and Meta-analysis. Pediatr Infect Dis J. 43(5): 467-476. https://doi.org/10.1097/INF.0000000000004258; PMid:38285519 PMCid:PMC11003409

17. WHO. (2026). Child mortality (under 5 years). URL: https://www.who.int/news-room/fact-sheets/detail/levels-and-trends-in-child-under-5-mortality-in-2020.